← All trials
NCT06059846
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Mar 31, 2026
- First posted
- Sep 29, 2023
- Last posted
- Sep 29, 2023
- Enrollment
- 2648
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spero TherapeuticsLead sponsor
- GlaxoSmithKlineCollaborator
- Spero TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.